News and Announcements
Apollo: Australia’s Premier Crypto Fund Set to Launch end of January
- Published January 12, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Information Memorandum to be distributed shortly
- All key relationships have been secured
- Team has been built out further
- Apollo Capital has been featured in the AFR and the Australian
The Apollo Capital Fund is to become the premier Australian crypto fund with institutional level oversight. We are quickly approaching launch date and the Information Memorandum is set to be distributed in the coming weeks. Thank you to all that have registered their interest!
All key relationships have been secured, including administrator Unity Fund Services, auditor RSM, legal counsel KHQ, tax advisors Pitcher Partners, registrar One Investment Group and data security experts SecureWorx.
The team has expanded further with the addition of Michael Parnell to the investment committee. Michael comes with a long history of successful crypto investing. Liam Aharon will also join the investment team. Liam has a very strong technical background and will strengthen our statistical arbitrage capabilities.
Apollo Capital has recently featured in the news. Henrik Andersson, CIO, wrote an interesting opinion piece in The Australian and the Fund’s launch was previewed by the Australian Financial Review.
About Australia’s Premier Crypto Fund
Australia’s First Crypto Fund will invest in a mixture of digital assets, including major cryptocurrencies like Bitcoin and Ethereum, and as well as Initial Coin Offerings (ICOs) and high growth opportunities.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
